Q3 2025 EPS Estimates for Pfizer Inc. (NYSE:PFE) Boosted by Zacks Research

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Zacks Research upped their Q3 2025 earnings per share estimates for Pfizer in a research report issued to clients and investors on Wednesday, June 26th. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will post earnings of $0.73 per share for the quarter, up from their prior estimate of $0.72. The consensus estimate for Pfizer’s current full-year earnings is $2.38 per share. Zacks Research also issued estimates for Pfizer’s FY2025 earnings at $2.61 EPS.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same period in the prior year, the firm earned $1.23 earnings per share. The firm’s revenue for the quarter was down 19.5% compared to the same quarter last year.

Other research analysts also recently issued reports about the company. Morgan Stanley lifted their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, June 26th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $35.54.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $28.22 on Monday. The firm has a 50 day moving average of $27.90 and a 200 day moving average of $27.69. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $159.91 billion, a price-to-earnings ratio of -470.25, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. Pfizer has a 52 week low of $25.20 and a 52 week high of $37.80.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.95%. Pfizer’s payout ratio is currently -2,799.53%.

Institutional Trading of Pfizer

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ironvine Capital Partners LLC raised its holdings in Pfizer by 2.1% in the 1st quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock worth $470,000 after purchasing an additional 353 shares during the period. Advisor OS LLC raised its stake in shares of Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after buying an additional 365 shares during the period. Safeguard Investment Advisory Group LLC lifted its position in shares of Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 371 shares in the last quarter. Lantz Financial LLC grew its stake in Pfizer by 1.3% in the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after acquiring an additional 381 shares during the period. Finally, Wellington Shields Capital Management LLC increased its holdings in Pfizer by 1.3% in the 1st quarter. Wellington Shields Capital Management LLC now owns 30,750 shares of the biopharmaceutical company’s stock worth $853,000 after acquiring an additional 385 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.